FBR Capital downgraded Galena Biopharma (NASDAQ: GALE) from Outperform to Market Perform with a price target of $4.00 (from $11.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE